Canadian non-profit TheraPsil has announced that patients and medical professionals from across Canada will be reaching out to Parliamentarians to raise awareness of the medical benefits of psilocybin.
The delegates will travel to Ottawa to seek more compassionate access to psilocybin for Canadian adults suffering from palliative depression, addiction, PTSD and chronic disease.
A meeting will be held to educate the public and recommend a transparent regulatory approach to guide medical access to psilocybin, just as was done for cannabis in 2000.
Spencer Hawkswell, CEO of TheraPsil, which works to expand safe, equitable and legal access to psilocybin-assisted therapy for those in medical need, commented: “With the worsening overdose crisis, pending MAiD expansion and our experience facilitating psilocybin treatment to over 134 patients over the past two years, we hope the federal Health Minister and other elected officials will provide vulnerable Canadians and health professionals with the right to try this effective natural treatment option.”
Media, elected officials, staff, sector leaders, patients and healthcare professionals are invited to attend the special event.
In addition to TheraPsil representatives, participants will include:
- Healthcare professionals that have prescribed psilocybin as a treatment for patients
- Canadians suffering from chronic disease that have received a medical exemption to possess psilocybin
- Canadians suffering from chronic disease that have been denied legal access to possess psilocybin for medical purposes
- Lawyers representing Canadians that have been denied medical access
- More activities will be announced over the coming days
The meeting will take place from 28 to 30 November, 2022 at Parliament Hill – Ottawa, Ontario and a special event will take place on Tuesday, 29 November, West Block, Room 225A from 5:30 pm to 7:30 pm.
